



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/917,222		
		Filing Date	July 27, 2001		
		First Named Inventor	GRANOFF, DAN M.		
		Art Unit	1645		
Sheet	1	of	2	Examiner Name	ZEMAN, ROBERT A.
				Attorney Docket Number	CHOR-001

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RZ	C1	Artenstein MS, et al, "Prevention of meningococcal disease by group C polysaccharide vaccine." N Engl J Med 1970;282:417-20.	
RZ	C2	Balmer P, et al, "Serologic correlates of protection for evaluating the response to meningococcal vaccines," Expert Rev Vaccines 2004;3:77-87	
RZ	C3	Borrow R, et al, "Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection," Infect Immun 2001;69:1568-73.	
RZ	C4	Densen P., "Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae," Clin Microbiol Rev 1989;2 Suppl:S11-7	
RZ	C5	De Wals P, et al, "Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec," Jama 2001;285:177-81.	

Examiner Signature		Date Considered	11/27/09
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	09/917,222		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	July 27, 2001		
		First Named Inventor	GRANOFF, DAN M.		
		Art Unit	1645		
		Examiner Name	ZEMAN, ROBERT A.		
Sheet	2	of	2	Attorney Docket Number	CHOR-001
RZ	C6	Figueroa JE, et al, "Infectious diseases associated with complement deficiencies," Clin Microbiol Rev 1991;4:359-95.			
RZ	C7	Fijen CA, et al, "Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups," Lancet 1989;2:585-8.			
RZ	C8	Frasch CE. "Meningococcal Vaccines: Past, Present and Future," In: Cartwright K, ed. Meningococcal Disease. New York: John Wiley & Sons, 1995:245-83			
RZ	C9	Gold R, et al, "Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70," Bull World Health Organ 1971;45:279-82			
RZ	C10	Goldschneider I, et al, "Human immunity to the meningococcus. II. Development of natural immunity," J Exp Med 1969;129:1327-48.			
RZ	C11	Harris SL, et al, "Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine," Infect Immun 2003;71:275-86			
RZ	C12	Holst et al., Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against <i>Neisseria meningitidis</i> serogroup B disease. Vaccine 2003, 21:734-737			
RZ	C13	Maslanka SE, et al. "Age-dependent <i>Neisseria meningitidis</i> serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine," Infect Immun 1998;66:2453-9.			
RZ	C14	Milagres LG, et al., "Immune response of Brazilian children to a <i>Neisseria meningitidis</i> serogroup B outer membrane protein vaccine: comparison with efficacy," Infect Immun 1994;62:4419-24.			
RZ	C15	Moe et al., Differences in surface expression of NspA among <i>Neisseria meningitidis</i> group B strains. Infect Immun 1999 67:5664-75			
RZ	C16	Nicholson A, Lepow IH. "Host defense against <i>Neisseria meningitidis</i> requires a complement- dependent bactericidal activity," Science 1979;205:298-9.			
RZ	C17	Pollard AJ, et al, "Development of natural immunity to <i>Neisseria meningitidis</i> ," Vaccine 2001;19:1327-46.			
RZ	C18	World Health Organization. Requirements for meningococcal polysaccharide vaccine (requirements for biological substances no. 23). WHO Tech Rep Ser 1976;594:72 - 73			
RZ	C19	50 Fed. Reg. 162, Guidelines for Production of Meningococcal Polysaccharide Vaccines Docket No. 84D-0263, Notice of Availability Published August 21, 1985			
Examiner Signature		Robert Zeman		Date Considered	11/29/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Please type a plus sign (+) inside this box:



PTO/SB/08A (08-00)


Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	09/917,222
		Filing Date	July 27, 2001
		First Named Inventor	Granoff et al.
		Group Art Unit	1645
		Examiner Name	N/A
Sheet	1	of	4
		Attorney Docket Number	CHOR-001

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
RZ	AA	4,601,903		Frasch	07-22-1986	
RZ	AB	4,727,136		Jennings, et al.	02-23-1988	
RZ	AC	5,705,161		Van Der Ley et al.	01-06-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
RZ	AD		0 449 958 B1		Seid et al.	03/22/95		
RZ	AE		WO 00/22430		Frazer et al.	04/20/00	(See CD-ROM)	
RZ	AF		WO 00/66791		Pizza et al.	02/09/00	(See CD-ROM)	
RZ	AG		WO 01/09350		Berthet et al.	02/08/01		
RZ	AH		WO 96/29412		Brodeur et al.	09/26/96		
RZ	AI		WO 98/02547		Nassif et al.	01/22/98		
RZ	AJ		WO 98/56901		Baldwin et al.	12/17/98		
RZ	AK		WO 99/24578		Masignani et al.	05/20/99	(See CD-ROM)	
RZ	AL		WO 99/36544		Masignani et al.	07/22/99		
RZ	AM		WO 99/57280		Fraser et al.	04/30/99	(See CD-ROM)	
RZ	AN		WO 99/61053		Granoff et al.	12/02/99		


Examiner Signature		Date Considered	11/29/04
-----------------------	---	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/917,222
		Filing Date	July 27, 2001
		First Named Inventor	Granoff et al.
		Group Art Unit	1645
		Examiner Name	N/A
		Attorney Docket Number	CHOR-001
Sheet	2	of	4

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RZ	AO	ASHTON, F. E. et al., 1938, "A New Serogroup (L) of <i>Neisseria meningitidis</i> ", <i>J. Clin. Microbiol.</i> 17: 722-727.	
RZ	AP	BORROW, et al., 2001, "Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the U.K.: Reevaluation of Correlates of Protection", <i>Infection and Immunity</i> , 69(3):1568-1573.	
RZ	AQ	BRANHAM, S. E., 1956, "Milestones in the History of Meningococcus", <i>Canadian Journal of Microbiology</i> , 2:175-188.	
RZ	AR	CAMPAGNE et al. 2000, "Safety and immunogenicity of three doses of a <i>Neisseria meningitidis</i> A + C diphtheria conjugate vaccine in infants from Niger", <i>Pediatric Infectious Disease Journal</i> , 19(2):144-150.	
RZ	AS	CARTWRIGHT K et al, 1999, "Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins", <i>Vaccine</i> , 17:2612-2619.	
RZ	AT	DE KLEINJN ED et al, 2000, "Immunogenicity and safety of a hexavalent meningococcal outer membrane-vesicle vaccine in children of 2-3 and 7-8 years of age", <i>Vaccine</i> , 18:1456-1466.	
RZ	AU	FRASCH, C. E. AND CHAPMAN, 1973, "Classification of <i>Neisseria meningitidis</i> Group B into Distinct Serotypes. III. Application of a New Bactericidal-Inhibition Technique to Distribution of Serotypes among Cases and Carriers" <i>Journal of Infectious Disease</i> , 127:149-154.	
RZ	AV	FUSCO et al., 1997, "Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in both Mice and Nonhuman Primates", <i>Journal of Infectious Diseases</i> , 175: 364-372.	
RZ	AW	GOLD et al., 1969-1970, "Meningococcal Infections" <i>Bull. WHO</i> , 45: 272-282.	
RZ	AX	GOLDSCHNEIDER et al, 1969, "Human Immunity to the Meningococcus: I. The Role of the Humoral Antibodies" <i>J. Exp. Med.</i> 129:1307-1326.	
RZ	AY	GOTSCHLICH et al., 1969, "Human Immunity to the Meningococcus: III. Preparation and Immunochemical Properties of the Group A, Group B, and Group C Meningococcal Polysaccharides", <i>J. Exp. Med.</i> 129:134-136.	
RZ	AZ	GRANOFF et al., 1998, "Bacterial Monoclonal Antibodies That Define Unique Meningococcal B Polysaccharide Epitopes That Do Not Cross-React with Human Polysialic Acid", <i>J. Immunol.</i> 160: 5028-5036.	
RZ	BA	GRANOFF et al., 1998, "Induction of Immunologic Refractoriness in Adults by Meningococcal C Polysaccharide Vaccination", <i>J. Infect. Dis.</i> 178(3): 870-4.	


Examiner Signature	<i>Robert Ziem</i>	Date Considered	11/29/04
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/917,222
		Filing Date	July 27, 2001
		First Named Inventor	Granoff et al.
		Group Art Unit	1645
		Examiner Name	N/A
		Attorney Docket Number	CHOR-001
Sheet	3	of	4

R2	BB	HANKINS, 1982, "Clinical and Serological Evaluation of a Meningococcal Polysaccharide Vaccine Groups A,C,Y, and W135 (41306), <i>Proc. Soc. Biol. Med.</i> 169: 54-57.	
R2	BC	HONG et al., 1981, "Inhibitory Effect of K-76 Monocarboxylic Acid, an Anticomplementary Agent, on the C3b Inactivator System" <i>J Immunol.</i> 127:104-108	
R2	BD	MACDONALD et al., 1998, "Induction of Immunologic Memory by Conjugated vs Plain Meningococcal C Polysaccharide Vaccine in Toddlers", <i>JAMA</i> 280:1685-1689	
R2	BE	MACDONALD et al., 2000, "Can Meningococcal C Conjugate Vaccine Overcome Immune Hyporesponsiveness Induced by Previous Administration of Plain Polysaccharide Vaccine?" <i>JAMA</i> 283:1826-1827	
R2	BF	MACLENNAN et al., 2000, "Safety, Immunogenicity, and Induction of Immunologic memory by a Serogroup C Meningococcal Conjugate Vaccine in Infants" <i>JAMA</i> 283: 2795-2801	
R2	BG	MAIDEN et al., 1998, "Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms", <i>Proc. Natl. Acad. Sci. USA</i> 95:3140-3145.	
R2	BH	MARTIN et al., 2000. "Candidate <i>Neisseria meningitidis</i> NspA vaccine", <i>J. Biotechnol.</i> 83:27-31	
R2	BI	MARTIN et al, 2000, "Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine", <i>Vaccine</i> , 18:2476-2481	
R2	BJ	MOE et al. 1999, "Differences in Surface Expression of NspA among <i>Neisseria meningitidis</i> Group B Strains", <i>Infection and Immunity</i> , 67:5664-5675.	
R2	BK	MOE et al. 2001, "Functional Activity of Anti- <i>Neisseria meningitidis</i> Surface Protein A Monoclonal Antibodies against Strains of <i>Neisseria meningitidis</i> Serogroup B", <i>Infection and Immunity</i> , 69:3762-3771.	
R2	BL	MILAGRES et al., 1994, "Immune Response of Brazilian Children to a <i>Neisseria meningitidis</i> Serogroup B Outer Membrane Protein Vaccine; Comparison with Efficacy", <i>Infection and Immunity</i> , 62: 4419-4424.	
R2	BM	PIZZA et al. 2000 "Identification of Vaccine Candidates Against Serogroup B <i>Meningococcus</i> by Whole-Genome Sequencing", <i>Science</i> 287:1816-1820.	
R2	BN	ROUPPE VAN DER VOORT et al., 2000, "Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys", <i>Vaccine</i> , 18:1334-1343.	
R2	BO	SACCHI et al., 1998, "Correlation between Serological and Sequencing Analyses of the PorB Outer Membrane Protein in the <i>Neisseria meningitidis</i> Serotyping System", <i>Clin. Diag. Lab. Immunol.</i> 5:348-354.	
R2	BP	SACCHI et al., 2000, "Diversity and Prevalence of PorA Types in <i>Neisseria meningitidis</i> Serogroup B in the United States", <i>Journal of Infectious Diseases</i> , 182:1169-1176.	


Examiner Signature	<i>Robert L. Zimm</i>	Date Considered	11/29/04
--------------------	-----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	4	Application Number	09/917,222
				Filing Date	July 27, 2001
				First Named Inventor	Granoff et al.
				Group Art Unit	1645
				Examiner Name	N/A
				Attorney Docket Number	CHOR-001

RZ	BQ	SAUKKONEN et al. 1988, "Monoclonal Antibodies to the Rough Lipopolysaccharide of <i>Neisseria meningitidis</i> Protect Infant Rats From Meningococcal Infection" <i>Journal of Infectious Diseases</i> , 158: 209-212.	
RZ	BR	SHAO-QING, et al., 1981, "Three new serogroups of <i>Neisseria meningitidis</i> ", <i>J. Biol. Stand.</i> 9: 307-315.	
RZ	BS	SLATERUS, K. W., 1961, Ant. V. Leeuwenhoek, "Types of Meningococcal Isolated from Carriers and Patients in a Non-Epidemic Period in the Netherlands", <i>J. Microbiol. Serol.</i> 29: 265-271	
RZ	BT	STEPHENS et al. 1991, "Insertion of Tn916 in <i>Neisseria meningitidis</i> Resulting in Loss of Group B Capsular Polysaccharide", <i>Infection and Immunity</i> , 59: 4097-4107	
RZ	BU	TAPPERO et al., 1999, "Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines", <i>JAMA</i> 281:1520-1572.	
RZ	BV	WYLE et al., 1972, "Immunologic Response of Man to Group B Meningococcal Polysaccharide Vaccines", <i>J Infect. Dis.</i> 126: 514-522.	
RZ	BW	ZOLLINGER, et al., 1979, "Complex of Meningococcal Group B Polysaccharide and Type 2 Outer Membrane Protein Immunogenic in Man", <i>J Clin. Invest.</i> 63: 836-848.	
RZ	BX	NAESS, et al. 1998, "Human T-Cell Response after Vaccination with the Norwegian Group B Meningococcal Outer Membrane Vesicle Vaccine" <i>Infection and Immunity</i> , Vol. 66(3): 959-965.	
RZ	BY	HANEBERG et al. 1998, "Intranasal Administration of a Meningococcal Outer Membrane Vesicle Vaccine Induces Persistent Local Mucosal Antibodies and Serum Antibodies with Strong Bactericidal Activity in Humans", <i>Infection and Immunity</i> , Vol. 66(4): 1334-1341.	
RZ	BZ	WEDEGE et al. 1998, "Immune Response against Major Outer Membrane Antigens of <i>Neisseria meningitidis</i> in Vaccines and Controls Contracted Meningococcal Disease during the Norwegian Serogroup B Protection Trail", <i>Infection and Immunity</i> , Vol. 66(7): 3223-3231.	
RZ	CA	LEHMANN et al. 1999, "Human Opsonins Induced during Meningococcal Disease Recognize Outer Membrane Proteins PorA and PorB", <i>Infection and Immunity</i> , Vol. 67(5):2552-2560.	
RZ	CB	ROSENQVIST et al. "Human Antibody Responses to Meningococcal Outer Membrane Antigens after three Doses of the Norwegian Group B Meningococcal Vaccine", <i>Infection and Immunity</i> , Vol. 63(12): 46-42-4652.	

Examiner Signature	<i>Robert Zeman</i>	Date Considered	11/29/04
--------------------	---------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.